Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 30, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 31, 2026
CEOTax withholding
Context
Classification
tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue
Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-037447
Filed / recorded
Mar 31, 2026, 8:10 PM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ORAMED PHARMACEUTICALS INC.
Issuer CIK
1176309
Ticker
ORMP
Reporting person
Nadav Kidron
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 30, 2026
Transaction code
F
Shares / units
44,818
Price per share
$3.31
Acquired / disposed
Disposed (D)
Shares owned after
3,422,243
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.